Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson's disease

Hisashi Uwatoko1, Yuka Hama2, Ikuko Takahashi Iwata2

  • 1Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, North 15 West 7, Kita-Ku, Sapporo, Hokkaido, 060-8368, Japan. uwatoko@pop.med.hokudai.ac.jp.

Molecular Brain
|May 16, 2019
PubMed

Insights

This study identified distinct microRNA (miRNA) profiles in Parkinson's disease (PD) and Multiple System Atrophy (MSA) patients. Specific miRNAs in plasma may help differentiate these neurodegenerative diseases.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • MicroRNAs (miRNAs) are crucial regulators of gene expression, and their dysregulation is implicated in various diseases.
  • Multiple System Atrophy (MSA) and Parkinson's disease (PD) are α-synucleinopathies with overlapping clinical symptoms, necessitating reliable biomarkers for differentiation.

Purpose of the Study:

  • To identify differentially expressed miRNAs in the plasma of patients with PD, MSA (cerebellar and postural subtypes), and healthy controls.
  • To explore the potential of these miRNAs as biomarkers for distinguishing between PD and MSA subtypes.

Main Methods:

  • Plasma samples were analyzed using microarray analysis to screen for differentially expressed miRNAs.
  • Quantitative expression levels of candidate miRNAs were validated using reverse transcription quantitative polymerase chain reaction (RT-qPCR).

Main Results:

  • Significant differences in plasma levels of hsa-miR-671-5p, hsa-miR-19b-3p, and hsa-miR-24-3p were observed among the groups.
  • Hsa-miR-671-5p levels were lower in MSA-P and PD compared to MSA-C and controls, distinguishing MSA subtypes.
  • Hsa-miR-19b-3p and hsa-miR-24-3p showed higher expression in PD, with a positive correlation between them.

Conclusions:

  • Hsa-miR-671-5p, hsa-miR-19b-3p, and hsa-miR-24-3p are potential plasma biomarkers for differentiating PD and MSA.
  • These miRNAs may reflect the underlying pathophysiology or clinical symptoms of these α-synucleinopathies.